Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
In 2004, several investigators reported that somatic mutations in the epidermal growth factor
receptor gene were associated with clinical responses to erlotinib and gefitinib in patients
with non–small cell lung cancer. Since then, multiple groups have examined the biological
properties that such mutations confer as well as the clinical relevance of these mutations in
patients with non–small cell lung cancer. Although a tremendous amount of knowledge has
been gained in the past 2 years, there remain a number of important epidemiologic …
receptor gene were associated with clinical responses to erlotinib and gefitinib in patients
with non–small cell lung cancer. Since then, multiple groups have examined the biological
properties that such mutations confer as well as the clinical relevance of these mutations in
patients with non–small cell lung cancer. Although a tremendous amount of knowledge has
been gained in the past 2 years, there remain a number of important epidemiologic …
Abstract
In 2004, several investigators reported that somatic mutations in the epidermal growth factor receptor gene were associated with clinical responses to erlotinib and gefitinib in patients with non–small cell lung cancer. Since then, multiple groups have examined the biological properties that such mutations confer as well as the clinical relevance of these mutations in patients with non–small cell lung cancer. Although a tremendous amount of knowledge has been gained in the past 2 years, there remain a number of important epidemiologic, biological, and clinical questions.
AACR